---
title: "Unicycive Therapeutics tumbles 8% after hours on FDA complete response letter"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291333372.md"
description: "UNCY down 8% after hours, 39% in regular session after FDA issues complete response letter over third-party manufacturing defects."
datetime: "2026-06-30T20:51:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291333372.md)
  - [en](https://longbridge.com/en/news/291333372.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291333372.md)
---

# Unicycive Therapeutics tumbles 8% after hours on FDA complete response letter

Unicycive Therapeutics(UNCY.US) 盘后跌超 8%，现报 4.60 美元。

该股正常交易时段大跌 39.09%。公司宣布收到 FDA 就其草酸镧 NDA 发出的完整回应函，原因是第三方供应商存在未解决的制造缺陷，审查期间未对该供应商进行检查。

该药物用于治疗透析慢性肾病患者的高磷酸盐血症。FDA 未提出新的安全或有效性问题，标签讨论仍在进行中。

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline](https://longbridge.com/en/news/294551506.md)
- [Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position](https://longbridge.com/en/news/291569499.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease pipeline, lead hyperphosphatemia drug OLC](https://longbridge.com/en/news/291838842.md)
- [Unicycive Therapeutics Gets Complete Response Letter From FDA On Resubmitted Oxylanthanum Carbonate NDA](https://longbridge.com/en/news/291272311.md)
- [Unicycive says FDA issues CRL for OLC NDA over third-party manufacturing deficiencies](https://longbridge.com/en/news/291271373.md)